Close Menu

NEW YORK – Roche Diagnostics announced on Wednesday that its SARS-CoV-2 Rapid Antigen Test received approval under Health Canada's Interim Order.

The rapid chromatographic immunoassay, which was developed by Korean diagnostic firm SD Biosensor, qualitatively detects the SARS-CoV-2 nucleocapsid protein in the nasopharynx and returns results in 15 minutes without an instrument. The test is intended to diagnose patients with SARS-CoV-2 within five days of symptom onset, Roche said in a statement. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.